Dacomitinib
Sign in to save this workspacePrimary targets: EGFR · FDA status: FDA Approved
Selectivity scorecard
KISS
97.99
Gini
0.664
CATDS
0.016
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Dacomitinib. Strongest target: ERBB4_HER4 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ERBB4_HER4 | 100.0% | 0.0% |
| 2 | EGFR | 99.8% | 0.2% |
| 3 | ERBB2_HER2 | 99.5% | 0.5% |
| 4 | TXK | 97.9% | 2.1% |
| 5 | DDR1 | 95.6% | 4.4% |
| 6 | BLK | 94.5% | 5.5% |
| 7 | JAK3 | 94.4% | 5.6% |
| 8 | LYN | 93.4% | 6.6% |
| 9 | LCK | 88.6% | 11.4% |
| 10 | BTK | 87.2% | 12.8% |
| 11 | DDR2 | 81.7% | 18.3% |
| 12 | ABL1 | 80.8% | 19.2% |
| 13 | EPHA6 | 79.1% | 20.9% |
| 14 | C_SRC | 76.6% | 23.4% |
| 15 | PEAK1 | 75.2% | 24.8% |
| 16 | ITK | 73.6% | 26.4% |
| 17 | FGR | 72.0% | 28.0% |
| 18 | EPHB4 | 71.4% | 28.6% |
| 19 | LOK_STK10 | 70.2% | 29.8% |
| 20 | YES_YES1 | 69.7% | 30.3% |
Selectivity landscape
Where Dacomitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Dacomitinib.
Atlas insights for Dacomitinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.848 |
| SRR23303752 | — | 0.840 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.831 |
| SRR10899984 | — | 0.829 |
| aMVAC.P_005_TURBT_S223 | — | 0.828 |
Annotations
Sign in to read and post annotations.
Loading…